Literature DB >> 15207257

Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse.

Joep H J Kamphoven1, Martijn M de Ruiter, Leon P F Winkel, Hannerieke M P Van den Hout, Jan Bijman, Chris I De Zeeuw, Hans L Hoeve, Bert A Van Zanten, Ans T Van der Ploeg, Arnold J J Reuser.   

Abstract

Hearing deficit occurs in several lysosomal storage disorders but has so far not been recognized as a symptom of Pompe's disease (glycogen storage disease type II). We discovered quite unexpectedly 30-90 dB hearing loss in four infants with Pompe's disease, who participated in a study on the safety and efficacy of enzyme replacement therapy. Three other patients with juvenile Pompe's disease did not have this symptom. The ABR (auditory brainstem response) thresholds but not the interpeak latency times were increased. This pointed to middle or inner ear pathology rather than to involvement of the central auditory nervous system. The possible occurrence of cochlear pathology was supported by the absence of oto-acoustic emissions. We investigated this hypothesis in a knockout mouse model of Pompe's disease and found glycogen storage in the inner and outer hair cells of the cochlea, the supporting cells, the stria vascularis, and the spiral ganglion cells. We conclude that cochlear pathology is the most likely cause of hearing loss in infantile Pompe's disease and possibly a characteristic feature of this clinical subtype.

Entities:  

Mesh:

Year:  2004        PMID: 15207257     DOI: 10.1016/j.nbd.2003.12.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  18 in total

Review 1.  Glycogen storage disease type II: clinical overview.

Authors:  M Di Rocco; D Buzzi; M Tarò
Journal:  Acta Myol       Date:  2007-07

Review 2.  Multisystem late onset Pompe disease (LOPD): an update on clinical aspects.

Authors:  Antonio Toscano; Carmelo Rodolico; Olimpia Musumeci
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  Long-term outcome and unmet needs in infantile-onset Pompe disease.

Authors:  Andreas Hahn; Anne Schänzer
Journal:  Ann Transl Med       Date:  2019-07

4.  CRIM-negative infantile Pompe disease: 42-month treatment outcome.

Authors:  Marianne Rohrbach; Andrea Klein; Alice Köhli-Wiesner; Dorothe Veraguth; Ianina Scheer; Christian Balmer; Roger Lauener; Matthias R Baumgartner
Journal:  J Inherit Metab Dis       Date:  2010-09-30       Impact factor: 4.982

Review 5.  TPCs: Endolysosomal channels for Ca2+ mobilization from acidic organelles triggered by NAADP.

Authors:  Michael X Zhu; Jianjie Ma; John Parrington; Antony Galione; A Mark Evans
Journal:  FEBS Lett       Date:  2010-02-14       Impact factor: 4.124

6.  Oropharyngeal dysphagia in infants and children with infantile Pompe disease.

Authors:  Harrison N Jones; Carolyn W Muller; Min Lin; Suhrad G Banugaria; Laura E Case; Jennifer S Li; Gwendolyn O'Grady; James H Heller; Priya S Kishnani
Journal:  Dysphagia       Date:  2009-09-10       Impact factor: 3.438

7.  Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1-deficient mice.

Authors:  Xudong Wu; Katherine A Steigelman; Erik Bonten; Huimin Hu; Wenxuan He; Tianying Ren; Jian Zuo; Alessandra d'Azzo
Journal:  Biochim Biophys Acta       Date:  2009-10-24

Review 8.  The acid test: the discovery of two-pore channels (TPCs) as NAADP-gated endolysosomal Ca(2+) release channels.

Authors:  Antony Galione; A Mark Evans; Jianjie Ma; John Parrington; Abdelilah Arredouani; Xiaotong Cheng; Michael X Zhu
Journal:  Pflugers Arch       Date:  2009-05-28       Impact factor: 3.657

9.  Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.

Authors:  Michael Beck
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

Review 10.  Calcium signaling via two-pore channels: local or global, that is the question.

Authors:  Michael X Zhu; Jianjie Ma; John Parrington; Peter J Calcraft; Antony Galione; A Mark Evans
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-16       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.